Immunotherapy before surgery for recurrent throat cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests whether a combination of immunotherapy and chemotherapy before surgery can help people whose throat cancer has come back after treatment. The goal is to shrink the tumor before surgery, which may improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have squamous cell carcinoma of the larynx (voice box) or hypopharynx (throat) that has returned after previous treatment.
- You must be at least 18 years old.
- You must be able to tolerate the chemotherapy drug cisplatin.
- You must have a good performance status (able to do daily activities without major limitation).
- You must have measurable disease, meaning the tumor can be assessed with imaging.
- Your organs must be functioning normally, and you must agree to use contraception if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (tirelizumab) with two chemotherapy drugs before surgery for head and neck cancer that has spread to lymph nodes. The goal is to shrink the tumor and improve treatment outcomes.
This trial tests a new combination for people whose head and neck cancer has come back after prior radiation. You'll receive an immunotherapy drug (pembrolizumab) plus radiation, then surgery. The goal is to see if this approach can improve how well surgery works.
This trial looks at whether continuing immunotherapy can help keep cancer from coming back in people with head and neck cancer who had a good response to chemo-immunotherapy before surgery. You would have already had surgery, and now the study tests a maintenance treatment to strengthen your immune system's fight against any remaining cancer cells.
This Phase 2 trial tests whether giving pembrolizumab (an immune therapy) plus chemotherapy before curative surgery can improve outcomes for people with resectable, recurrent head and neck squamous cell cancer. It also studies how these treatments affect the tumor and immune response using required tissue and blood samples.
This trial tests whether giving a combination of an immunotherapy drug (PD-1 inhibitor) and chemotherapy before surgery can help treat advanced throat cancer. The goal is to see if this approach shrinks tumors and improves outcomes.
This trial tests a new combination of drugs (an immunotherapy called a PD-1 inhibitor, cetuximab, and platinum chemotherapy) given before surgery for advanced throat cancer that requires removing the voice box. The goal is to see if this treatment shrinks the tumor and improves outcomes.
Hear when a new Head and Neck Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.